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A manic episode after bilateral subthalamic stimulation in a patient with
advanced Parkinson’s disease.
Deep brain stimulation (DBS) has proven to be an effective treatment
for patients with refractory symptoms in the advanced stages of
Parkinson’s disease. However, different psychiatric and cognitive
problems may occur after DBS. We report a case of a manic episode
after DBS of the subthalamic nucleus in a patient with advanced
Parkinson’s disease. After slow and gradually restart of the
neurostimulation using the lowest effective intensity, the motor
symptoms remained sufficiently under control without causing any
psychiatric problems.
Parkinson’s disease (PD) is a common progressive
neurodegenerative disorder leading to increasing motor
disability (1,2). The main clinical features include
asymmetric resting tremor, rigidity, bradykinesia,
postural instability and gait abnormalities. In addition,
in later stages of the disorder, cognitive and beha-
vioural problems may become a serious burden (e.g.
depression, bradyphrenia and psychotic symptoms).
Multiple neurotransmitter systems degenerate in PD,
but the loss of dopaminergic neurons in the substantia
nigra is considered as a major cause of the sym-
ptomatology, especially the motor symptoms (3).
Long-term pharmacological treatment is often
associated with the development of several side effects
such as motor fluctuations and abnormal movements
(e.g. dyskinesia). More recently, deep brain stimulation
(DBS) has proven to be an effective treatment, in
particular, for patients with such refractory symptoms in
advanced stages of the disease. DBS has targeted
different brain area including the ventro intermediate
nucleus of the thalamus, the globus pallidus internus and
the subthalamic nucleus (STN). Nowadays, the STN is
generally accepted to be the target of choice, because of
its beneficial effects on all cardinal motor symptoms and
its potential to reduce medication dosage (4).
Despite the promising results several complications
of DBS have been reported. They vary from surgery-
related (e.g. intracerebral hemorrhage, infection),
to hardware-related (e.g. lead breaking, stimulator
malfunction) and stimulation-related (e.g. dyskinesia,
blepharospasm and speech disturbances) problems
(4,5). Furthermore, a number of different psychiatric
and cognitive problems have been reported with
DBS: depression (8%), transient hypomania (8%),
manic episodes (4%) and, to a lesser extent, anxiety
disorders, personality changes, apathy and aggressive
behaviours (3,5).
Case report
A 68-year-old man with a 12-year history of
Parkinson’s disease (PD) was treated with
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subthalamic DBS because of motor fluctuations and
increasing off episodes characterised by severe
rigidity. Additionally, he had camptocormia during
both on and off phases. In the early stages of the
illness he showed more prominent motor symptoms
in the right hemisoma but over the years he
developed bilateral and especially axial symptoms.
He has consecutively been treated with different
combinations of pergolide, amantadine, levodopa,
entacapon and rasagiline. Although he had prominent
axial symptomatology with camptocormia, he was
considered for DBS in view of the increasing and
debilitating off episodes.
The pre-operative Unified Parkinson’s Disease
Rating Scale (UPDRS) motor scores were 48 and 74
in the on and off phase, respectively. The high motor
score was mainly due to the axial symptomatology.
Extensive neuropsychological testing displayed only
minor executive dysfunction as can be seen with PD.
No signs indicative of more widespread cognitive
deficits were found. The pre-operative score of the
first part of the UPDRS, mentation, behaviour and
mood, was 3. The patient was daily treated with
a combination of levodopa (63 150mg), carbidopa
(63 37.5mg), entacapon (63 200mg), pergolide
(63 1mg), rasagiline (13 1mg) and amantadine
(13 100mg).
His past medical history showed a benign prostate
hypertrophy, low back pain and one episode of
transient global amnesia. He had never demonstrated
any psychiatric disorder, nor did the family members
reported any neurological or psychiatric disorders.
The pre-operative MRI of the brain showed no
abnormalities.
Deep brain electrodes were stereotactically
implanted in both subthalamic nuclei, using a con-
ventional planning based on MRI and Schaltenbrandt
coordinates. In addition, a microelectrode recording
with five microelectrodes was used to determine the
optimal target. Finally, intra-operative stimulation and
clinical testing was used to verify the optimal location,
based on clinical effects on the cardinal symptoms and
the large threshold for evoking stimulation-induced side
effects. Indirect targeting with the mid-commissural
point as the origin of stereotactic space was used. The
final electrode location was defined after verification by
means of microrecordings and macrostimulation. The
left electrode was placed in the calculated trajectory,
while macrostimulation 2mm more laterally elicited a
speech disturbance (corresponding with the internal
capsule). The right electrode was placed 2mm anterior
to the calculated trajectory, because macrostimulation
in the central trajectory elicited paresthesiae and
macrostimulation 2mm lateral from the latter elicited
a speech disturbance. The implantation procedure was
uneventful. In a second intervention, one week later, the
pulse generator was implanted and the extensions were
internalised. A gradual increase of the current output
was clinically tested and finally the patient was
stimulated with a voltage of 2V bilaterally. Motor
symptoms, including the camptocormia, significantly
improved. The post-operative UPDRS motor score was
28 without medication. The patient was able to walk
without walking aid.
Freezing, tremor, rigidity and even dysarthria
markedly improved. The antiparkinson medication
was discontinued. Two weeks after the electrode
implantation the patient was discharged from the
hospital.
Four weeks later, the patient was urgently
admitted to the hospital with important behavioural
changes. He was not able to sleep at night and
slept only 1–2 h during the daytime. His mood
was elevated. He had logorrhea. His behaviour was
impulsive (buying lots of things) and disinhibited
(making inappropriate sexual comments). Psycho-
motor activity was increased and the patient was
agitated (‘working in the garden at night’, ‘climbing
on the roof of the house y’). Furthermore,
grandiose ideas (building a swimming pool on top
of his flat) were present. The patient had no insight
in his behavioural changes and felt fantastic. No
hallucinations or suicidal ideas were present. The
partner of the patient mentioned retrospectively that
after the discharge from the hospital, the patient only
slept for 4 h per night and that his mood was a bit
elevated but not problematic. Initially, this was
ascribed to his feelings of relief after the surgical
procedure. The patient was diagnosed with a manic
episode, probably elicited by DBS. Consequently,
the DBS was turned off. Motor symptoms including
rigidity and camptocormia rapidly re-appeared but
all behavioural changes disappeared. Because of
the motor symptoms, the DBS was again initiated
and gradually but more slowly increased to 1.5V
bilaterally. This stimulation sufficiently controlled
the motor symptoms without causing any behavioural
problems and any need for further antiparkinson
medication. Only trazodone 100mg was daily given
for sleep difficulties.
Discussion
Chronic bilateral DBS of the STN is an effective
neurosurgical procedure for treatment of serious
motor symptoms in patients with advanced PD,
which cannot be sufficiently treated with pharmaco-
logical medication (5). However, several psychiatric
complications have been reported after DBS. The
most frequent problems are cognitive dysfunction
and depression. Hypomanic or manic symptoms are
relatively rare but may occur in about 4–8% of the
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patients undergoing DBS (1,2,5). They often start
soon after the initiation of the stimulation and are
mostly transient (2,5).
Several hypotheses have been put forward to
explain the (hypo)manic symptoms after DBS. They
may result from a pre-existing psychiatric illness,
surgery-related stress or the neurostimulation (5).
No pre-existing psychiatric illness was present in
our patient. Any type of surgery may cause stress,
but the surgical procedure went without any compli-
cations and resulted in significant motor improve-
ments making it less likely the cause of the manic
episode in our patient. Since all antiparkinson
medication was discontinued after DBS, a drug-
induced manic episode is highly unlikely. One
would also expect rather depressive than manic
symptoms after discontinuation of antiparkinson
medication (5). The most likely hypothesis for the
occurrence of the manic episode in our patient is the
stimulation of the STN itself. It may be explained
by the anatomical relation between the neural
structures of the motor, the associative and limbic
pathways within the STN (2,3). Cognitive and
limbic information related to the basal ganglia is
processed by the associative and limbic circuits,
respectively. The STN has a central position within
these circuits. Additionally, these circuits are
represented within the STN by specific groups of
neurons located medially (limbic) and ventromedially
(associative). The STN probably has a regulatory
function in the processing of associative and limbic
information towards the cortical and subcortical
regions (3).
Neurophysiological and neuroimaging studies
suggest that emotional, cognitive and motor compo-
nents of behaviour are integrated and distributed
within the STN (2,3). Minor modifications in these
circuits, such as those evoked by DBS, may result in
behavioural changes like manic symptoms.
It may also be possible that a lower stimulation
intensity, resulting in a smaller electrical field,
affects the cognitive and limbic pathways to a
lesser extend compared to a larger electrical field. Yet
another mechanism may be involved. In our patient the
stimulation of the DBS was relatively rapidly increased
over the course of seven days to 2V. The manic
symptoms did not return when the DBS stimulation
was more gradually and more slowly increased to
1.5V. This may further point to the importance of slow
and gradual initiating the neurostimulation in order to
avoid psychiatric symptoms.
Conclusion
Manic episodes may occur after STN stimulation in
patients with PD. Although further research will be
necessary, a manic episode may be prevented by a
slow and gradual increase of the neurostimulation
and using the lowest effective intensity to control the
motor symptoms.
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